Pringles Parent Kellanova Tops Q4 Earnings Estimates, Despite Sluggish Sales In North America And Europe

Benzinga
02-07

Kellanova (NYSE:K) shares are trading relatively flat on Thursday.

The company reported fourth quarter adjusted earnings per share of 92 cents, beating the street view of 83 cents.

Quarterly sales of $3.12 billion (down 1.6%) outpaced the analyst consensus estimate of $3.10 billion. Organic net sales rose 7% year over year to $3.396 billion.

Kellanova North America’s net sales fell 2%, impacted by price/mix and currency, but offset by volume growth. Europe also saw a 2% decrease, due to currency and lower volume, despite price/mix growth.

Latin America’s fourth quarter net sales dropped 8% from currency impacts, partially offset by price/mix growth. AMEA’s net sales increased by 2%.

Also Read: ‘Tariffs Are A Means To An End’: Bessent Defends Trade Strategy, Pushes Growth Plan

Organic net sales growth was driven by strong performance in emerging markets. Developed markets showed improvement in volume and sales, despite slower-than-expected demand recovery.

“A more growth-oriented portfolio and solid execution by our entire organization once again contributed to stand-out quarterly performance, as we concluded our first full year as Kellanova,” commented Steve Cahillane, Kellanova’s Chairman, President, and Chief Executive Officer.

Adjusted operating profit increased by 20%, excluding currency translation. The company exited the quarter with cash and equivalents worth $694 million and inventories worth 1.165 billion.

Long-term debt at the end of the quarter totaled $4.998 billion. Kellanova did not provide forward-looking guidance due to its pending merger with Mars, Incorporated.

Price Action: K shares are trading higher by 0.12% to $81.96 at last check Thursday.

Read Next:

  • Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10